Happy Wednesday! Since October started, markets have been in a whirlwind. But we can largely attribute that to the bold character of President Trump who has — in only the last 7 days — contracted COVID-19, scared the shit out of Wall Street, made a full recovery, and then called off stimulus talks which were largely supporting stock valuations.

However, despite all the turbulence on markets, there are still winners. We’re breaking down the big ones:

🧬 This morning, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their development of a method for genome editing. CRISPR/Cas9 has been heralded as a potential way to fix genetic disorders, create personalized medicine and even attack cancer and viruses. The importance of Doudna and Charpentier’s discovery cannot be underscored. It opens up a world of possibilities.

🧬 A few years ago, after the discovery of the CRISPR/Cas9 system, Doudna and Charpentier set out to apply this science by co-founding a number of biotech companies. Simultaneously, researcher Feng Zhang also filed a U.S. patent on the technology after proving the CRISPR/Cas9 system worked in mammalian cells. That patent has become the center of a patent battle which has plagued the CRISPR IP. This is problematic given that there is no shortage of biotechs licensing the pivotal research from different parties.

Today, on news of the award ⬇️

🧪 $NTLA, founded by Doudna, is up 20%

🧪 $CRSP Therapeutics, co-founded by Charpentier, is up 11%.

🧪 $EDIT, founded by Feng Zhang, is up nearly 11%. Editas also was founded in-part by Doudna and several other scientists.

One thing is certain: the future of CRISPR science looks bright. Many of these companies are years from pivotal trials. But rest assured, the science itself is groundbreaking. And we will be following it — as we have been — for years to come. 📈📈📈

Author Profile Picture

Noah Weidner

Noah Weidner is a restless self-starter with a vehement interest in all things that make the world go around: culture, politics, economics and all the people in between. He writes the Bullish Rippers series and covers other interesting trends and happenings at Bullish.

What Did You Think?

Join The Discussion

Be the first to Comment!


Leave your comment:

Stocks Mentioned

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies.Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis.The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland. (From: StockAnalysis.com)